Scholar Rock Files Q1 2025 10-Q

Ticker: SRRK · Form: 10-Q · Filed: May 14, 2025 · CIK: 1727196

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

SRRK Q1 10-Q filed. Financials updated.

AI Summary

Scholar Rock Holding Corp. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and operational updates. Key financial figures include cash and cash equivalents, and changes in retained earnings and additional paid-in capital over the reporting periods.

Why It Matters

This filing provides investors with the latest financial health and operational status of Scholar Rock, a biopharmaceutical company, which is crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Scholar Rock is subject to inherent risks related to drug development, clinical trials, and regulatory approvals.

Key Numbers

Key Players & Entities

FAQ

What were the total revenues for the quarter ending March 31, 2025?

The provided excerpt does not contain specific revenue figures for the quarter ending March 31, 2025.

What is the company's net income or loss for the first quarter of 2025?

The filing excerpt does not detail the net income or loss for the first quarter of 2025.

Were there any significant changes in the company's debt structure during the quarter?

The provided text does not specify any changes to the company's debt structure.

What is the current cash burn rate of Scholar Rock?

Information regarding the cash burn rate is not explicitly stated in this excerpt.

What are the key clinical development programs mentioned in this filing?

This excerpt does not provide details on specific clinical development programs.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Scholar Rock Holding Corp (SRRK).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing